

Appendix S: Information to facilitate discussion of risks and benefits of treatments for people with psoriasis

Data are provided for the proportions of people achieving remission, withdrawing due to adverse events and experiencing specific adverse events (as prioritised by the GDG) for interventions that have been recommended in this guideline. Data are based on pooled estimates where possible and from trials with populations and dosing appropriate to the intervention. For full details of the duration of treatment and dosing schedules please refer to the main text of the guideline.

Text is in grey when the GDG had very low confidence in the absolute estimates, for example due to confounding and inadequate sample size.

S.1 Topical therapies (short term)

Intervention	Population – psoriasis phenotype	N achieving remission (clear/nearly clear or PASI75)			N experiencing:					
		Intervention	Placebo	Active comparator [†]	Withdrawal due to drug toxicity			Serious/named adverse events		
					Intervention	Placebo	Active comparator [†]	Intervention	Placebo	Active comparator [†]
Vitamin D or vitamin D analogues	Chronic plaque psoriasis of trunk and limbs	OD: 220/1000 BD: 487/1000	OD: 76/1000 BD: 122/1000	-	OD or BD: 23/1000	OD or BD: 29/1000	-	Skin atrophy BD: 1.9/1000	Skin atrophy BD: 3.2/1000	-
	Children with chronic plaque psoriasis of trunk and limbs	BD:605/1000	BD:441/1000	-	NA	NA	-	NA	NA	NA
	Scalp psoriasis	OD: 387/1000	OD: 219/1000	-	OD: 81/1000	OD: 52/1000	-	NA	NA	NA
Potent corticosteroids	Chronic plaque psoriasis of trunk and limbs	OD or BD: 394/1000	OD or BD: 77/1000	-	OD: 10/1000 BD:	OD: 79/1000 BD: 0/1000	-	Skin atrophy OD or BD:	Skin atrophy OD or BD:	-

Intervention	Population –	N achieving remission (clear/nearly clear			N experiencing:					
					25/1000			5.5/1000	0/1000	
	Scalp psoriasis	OD or BD: 632/1000	OD or BD: 223/1000	-	OD or BD: 9.5/1000	OD or BD: 41/1000	-	NA	NA	NA
Vitamin D or analogue and potent steroid, applied one in the morning and one in the evening	Chronic plaque psoriasis of trunk and limbs	611/1000	NA	Calcipotriol BD 469/1000	13/1000	NA	Calcipotriol BD: 26/1000	NA	NA	NA
Combined vitamin D or analogue and potent steroid	Chronic plaque psoriasis of trunk and limbs	OD: 494/1000	NA	Vit D OD: 193/1000	OD: 7.5/1000	NA	Vit D OD or BD: 27/1000	Skin atrophy OD: 4.2/1000	NA	Skin atrophy Vit D BD: 1.8/1000
	Scalp psoriasis	OD: 800/1000	OD: 500/1000	-	OD: 17/1000	OD: 0/1000	-	NA	NA	-
Very potent corticosteroids	Chronic plaque psoriasis of trunk and limbs	OD or BD: 625/1000	OD or BD: 13/1000	-	OD or BD: 4.6/1000	OD or BD: 6.0/1000	-	Skin atrophy OD or BD: 23/1000	Skin atrophy OD or BD: 0/1000	-
	Scalp psoriasis	OD or BD: 646/1000	OD or BD: 80/1000	-	OD or BD: 0/1000	OD or BD: 5.9/1000	-	Skin atrophy OD or BD: 0/1000	Skin atrophy OD or BD: 11/1000	-
Tazarotene	Chronic plaque psoriasis of trunk and limbs	OD: 58/1000	OD: 20/1000	-	OD: 107/1000	OD: 44/1000	-	Skin atrophy: OD: 0/1000	Skin atrophy OD: 0/1000	-

Intervention	Population –	N achieving remission (clear/nearly clear			N experiencing:						
Short-contact dithranol*	Chronic plaque psoriasis of trunk and limbs	OD: 430/1000	NA	Calcipotriol BD: 588/1000	OD: 82/1000	NA	Calcipotriol BD: 39/1000	NA	NA	NA	NA
Coal tar	Chronic plaque psoriasis of trunk and limbs	OD or BD: 111/1000 to 519/1000 depending on formulation and follow- up	NA	Calcipotriol BD: 214/1000 to 723/1000 depending on follow- up	OD or BD: 0-56/1000 depending on formulation and follow- up	NA	Calcipotriol BD: 0-40/1000 depending on follow- up	NA	NA	NA	NA
Tacrolimus	Psoriasis of the face and flexures	BD: 652/1000	BD: 309/1000	-	BD: 0/1000	BD: 25/1000	-	NA	NA	-	-
Pimecrolimus	Psoriasis of the flexures	BD: 714/1000	BD: 207/1000	-	BD: 0/1000	BD: 0/1000	-	Skin atrophy BD: 0/1000	Skin atrophy BD: 0/1000	-	-

[†] An active comparator will only be included if no placebo comparison is available; the standard intervention will be chosen if multiple active comparators are available

NA: Not available

-: Active comparison not reported as placebo comparison was available

*2/3 studies reported home-use of dithranol and in 1/3 studies the setting was unclear

OD: Once daily

BD: Twice daily